+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension



Acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, in patients with pulmonary arterial hypertension



Heart and Vessels 25(2): 144-149



We have previously demonstrated that long-term inhibition of Rho-kinase ameliorates pulmonary arterial hypertension (PAH) in animal models. In the present study, we examined acute vasodilator effects of inhaled fasudil, a specific Rho-kinase inhibitor, as a more feasible option to locally deliver the drug for PAH. We examined 15 patients with PAH (13 women and 2 men, 45 +/- 4 years old), including idiopathic PAH (n = 5), PAH associated with connective tissue disease (n = 6), PAH with congenital heart disease (n = 3), and portal PAH (n = 1). In those patients, we performed right heart catheterization with a Swan-Ganz catheter in the two protocols with inhalation of nitric oxide (NO) (40 ppm, 10 min) and fasudil (30 mg, 10 min) with a sufficient interval (>30 min). Both NO and fasudil inhalation significantly reduced mean pulmonary arterial pressure (PAP) (NO: P < 0.01, fasudil: P < 0.05) and tended to decrease pulmonary vascular resistance (NO: P = 0.07, fasudil: P = 0.1), but did not affect cardiac index. The ratio of pulmonary to systemic vascular resistance was significantly reduced both in NO and fasudil inhalation (NO: P < 0.01, fasudil: P < 0.05), indicating that both NO and fasudil inhalation selectively affect lung tissues. Interestingly, there was no correlation in the vasodilator effects between NO and fasudil, and a positive correlation with serum levels of high-sensitivity C-reactive protein was noted for fasudil but not for NO. These results suggest that inhalation of fasudil is as effective as NO in patients with PAH, possibly through different mechanisms.

(PDF emailed within 0-6 h: $19.90)

Accession: 051365920

Download citation: RISBibTeXText

PMID: 20339976

DOI: 10.1007/s00380-009-1176-8


Related references

Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart 91(3): 391-392, 2005

Acute effects of Rho-kinase inhibitor fasudil on pulmonary arterial hypertension in patients with congenital heart defects. Circulation Journal 79(6): 1342-1348, 2016

Acute vasodilator effect of fasudil, a Rho-kinase inhibitor, in monocrotaline-induced pulmonary hypertension in rats. Journal of Cardiovascular Pharmacology 49(2): 85-89, 2007

Oral sildenafil is an effective and specific pulmonary vasodilator in patients with pulmonary arterial hypertension: Comparison with inhaled nitric oxide. Circulation 105(20): 2398-2403, May 21, 2002

Liposomal fasudil, a rho-kinase inhibitor, for prolonged pulmonary preferential vasodilation in pulmonary arterial hypertension. Journal of Controlled Release 167(2): 189-199, 2013

Beneficial acute effects of rho-kinase inhibitor in patients with pulmonary arterial hypertension. Circulation Journal 70(2): 174-178, 2006

Acute pulmonary vasodilator testing with inhaled treprostinil in children with pulmonary arterial hypertension. Pediatric Cardiology 34(4): 1006-1012, 2013

Effects of the Rho-kinase inhibitor, fasudil, on pulmonary hypertension. Circulation Journal 79(6): 1213-1214, 2016

Acute effects of intravenous fasudil with different dosage on patients with congenital heart defects and severe pulmonary arterial hypertension. Zhonghua Yi Xue Za Zhi 98(9): 678-681, 2019

Rho-kinase inhibitor, fasudil, reduces pulmonary vascular resistance in patients with severe pulmonary hypertension. Circulation 108(17 Supplement): IV-525, October 28, 2003

Analysis of pulmonary vasodilator responses to the Rho-kinase inhibitor fasudil in the anesthetized rat. American Journal of Physiology. Lung Cellular and Molecular Physiology 295(5): L828-L836, 2008

Effects of intervention with Rho kinase inhibitor fasudil on rats with hypoxic pulmonary hypertension. Zhonghua Er Ke Za Zhi 44(12): 946-947, 2007

Inhaled Rho-kinase inhibitor is more effective than inhaled nitric oxide as a selective vasodilator in hypoxic pulmonary hypertensive rats. Circulation 108(17 Supplement): IV-10-IV-11, October 28, 2003

Acute Effects of Inhaled Iloprost in Pulmonary Arterial Hypertension Patients with Lung Disease. Journal of Cardiac Failure 23(10): S65-S66, 2017

Inhaled Fasudil Lacks Pulmonary Selectivity in Thromboxane-Induced Acute Pulmonary Hypertension in Newborn Lambs. Journal of Cardiovascular Pharmacology and Therapeutics: 1074248418772814-1074248418772814, 2018